Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,731.60
(
1.56%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
103.92
(
0.22%
)
Bitcoin
79,316.55
(
0.04%
)
News Focus
News Focus
Post# of 257556
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 92044

Wednesday, 04/21/2010 2:28:34 PM

Wednesday, April 21, 2010 2:28:34 PM

Post# of 257556
ASCO will have something on the potentially registrational phase-2 trial of ABT-888 in Stage III/IV melanoma, according to today’s ABT CC. This is the trial in question:

http://clinicaltrials.gov/ct2/show/NCT00804908

ABT-888 is a dual PARP inhibitor that ABT acquired in the Facet Biotech deal.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today